Factor VIIIproducts and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review-Reference-Cited by-同舟云学术

Factor VIIIproducts and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review

Published:2018-05-24 Issue:6 Volume:16 Page:1055-1068
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Hassan S.¹,Cannavò A.¹²,Gouw S. C.¹³,Rosendaal F. R.¹,van der Bom J. G.¹⁴

Affiliation:

1. Department of Clinical Epidemiology Leiden University Medical Center Leiden the Netherlands

2. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Luigi Villa Foundation Milan Italy

3. Department of Pediatric Hematology Emma Children's Hospital Academic Medical Center Amsterdam the Netherlands

4. Center for Clinical Transfusion Research Sanquin Research Leiden the Netherlands

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14124

Reference59 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. The past and future of haemophilia: diagnosis, treatments, and its complications

3. Impact of inhibitors on hemophilia a mortality in the United States

4. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

5. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS);Research and Practice in Thrombosis and Haemostasis;2024-05

2. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study;Hematology;2024-02-20

3. Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A;Haemophilia;2023-11-17

4. Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy;Current Gene Therapy;2023-04

5. Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII;Clinical and Applied Thrombosis/Hemostasis;2023-01